ReviewReumatologia2018
Interstitial lung disease in systemic sclerosis: challenges in early diagnosis and management.
Review in Reumatologia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Review
- [Connective tissue disease-associated interstitial lung diseases : A pattern-based approach to diagnosis].Radiologie (Heidelberg, Germany) · 2025Review
- Overlap syndrome involving rheumatoid arthritis and systemic sclerosis complicated by Hashimoto's thyroiditis and interstitial lung disease detected in primary care: a case report.AME case reports · 2025Article
- Systemic sclerosis associated interstitial lung disease: a survey of current practices in France.Therapeutic advances in musculoskeletal disease · 2023Article
- Downregulation of long noncoding RNA CASC15 inhibits progression, migration and invasion of papillary thyroid cancer.Archives of medical science : AMS · 2023Article
- Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment.Rheumatology (Oxford, England) · 2022Article
- Assessment of disease outcome measures in systemic sclerosis.Nature reviews. Rheumatology · 2022Review
- Systemic Scleroderma-Definition, Clinical Picture and Laboratory Diagnostics.Journal of clinical medicine · 2022Review
- Osteopetrosis in a Patient of Systemic Sclerosis Sine Scleroderma: A Rare Association.The Indian journal of radiology & imaging · 2021Article
- Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update.Journal of clinical medicine · 2020Review
- Lung function is associated with minimal EQ-5D changes over time in patients with systemic sclerosis.Clinical rheumatology · 2020Observational
- [Treatment of systemic sclerosis-associated interstitial lung disease].Zeitschrift fur Rheumatologie · 2020Review
- Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease.American journal of respiratory and critical care medicine · 2020Article
- Patient and Physician Perspectives on Systemic Sclerosis-Associated Interstitial Lung Disease.Clinical medicine insights. Circulatory, respiratory and pulmonary medicine · 2020Article
- The economic burden of systemic sclerosis related pulmonary arterial hypertension in Australia.BMC pulmonary medicine · 2019Article
- Detection and classification of systemic sclerosis-related interstitial lung disease: a review.Current opinion in rheumatology · 2019Review
- Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention.Open access rheumatology : research and reviews · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interstitial lung disease (ILD) is a group of lung diseases characterized by thickening of the interstitium surrounding pulmonary alveolar walls. It is related to specific radiographic features in lung imaging and/or the presence of restrictive disorders in pulmonary function tests (PFTs). ILD is one of the leading causes of death in systemic sclerosis patients. Major risk factors of ILD associated with SSc (SSc-ILD) include male sex, diffuse type of cutaneous SSc and presence of anti-Scl-70 antibodies. SSc-ILD is challenging to diagnose at an early stage as the symptoms are non-specific. The greatest risk of its development is during the 4-5 years after the initial diagnosis of systemic sclerosis. Clinical vigilance at the time, including regular pulmonary function tests and/or high-resolution com-puted tomography (HRCT), is needed. The aim of this paper is to summarize the current knowledge on early diagnostic methods and progression risk factors for SSc-ILD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.